The possibility of using mastodynon after endoprosthetics of mammary glands

Authors

  • Л. С. Сотникова Siberian State Medical University of the Ministry of Health of Russian Federation; ISPE “Women’s Health”, Tomsk, Russian Federation, Russian Federation
  • А. А. Сотников Siberian State Medical University of the Ministry of Health of Russian Federation, Tomsk, Russian Federation
  • Е. В. Удут Federal state budgetary institution “Scientific Research Institute of Pharmacology”, Tomsk, Russian Federation, Russian Federation
  • О. С. Тонких “International Institute of Biological Systems – Tomsk” Ltd, Tomsk, Russian Federation, Russian Federation

DOI:

https://doi.org/10.18370/2309-4117.2016.29.94-99

Keywords:

benign breast diseases, breast endoprosthetics, mathematical model, Mastodynon®

Abstract

The study to evaluate the efficacy of the drug Mastodynon® in treatment of benign mammary dysplasia after endoprosthetics was performed. Presented effective quality mathematical model of diagnostics and monitoring of dyshormonal breast pathology treatment, also after endoprosthetics of mammary glands.

During the period from 2009 to 2013 85 women of reproductive age before and after the endoprosthetics of the mammary glands were included in the study. A clinical study (phase IV) was a prospective, randomized, and monocenter. A study group comprised 58 patients with a diagnosis of “diffuse dyshormonal mammary dysplasia.” Effectiveness of Mastodynon® treatment for this disease was evaluated with the use of diagnostic mathematical model. In 33 patients of the main group Mastodynon® used for treatment for 12 weeks and up to 6 months for further follow-up. The control group include 25 women from the main group who did not receive conservative treatment. The control group consisted of 27 healthy women, comparable with the main group for age, without somatic, breast and gynecological pathologies.

Obtained decision rules in the diagnostic tables provide quality recognition in 87–94% of cases, which allows based on the developed by the authors mathematical model to objectively diagnose and assess the effectiveness of the dyshormonal breast pathology therapy.

The results showed high efficiency of Mastodynon® treatment of benign diffuse dyshormonal breast dysplasia for 3 months in women after total endoprosthetics. Criteria for evaluating of the effectiveness were not only clinical symptoms but also objective echographic indicators (thickness of premammary tissue, fibroglandulyar layer and retromammary tissue).

The study also significantly showed that the lack of treatment in women with dyshormonal breast pathology after endoprosthetics leads to an unfavorable progression of the main signs of clinical and sonographic characteristics of the disease.

Author Biographies

Л. С. Сотникова, Siberian State Medical University of the Ministry of Health of Russian Federation; ISPE “Women’s Health”, Tomsk, Russian Federation

MD, professor at the Obstetrics and Gynecology Department; head

А. А. Сотников, Siberian State Medical University of the Ministry of Health of Russian Federation, Tomsk

MD, professor at the Department of Plastic Surgery with a Course of Operative Surgery and Topographic Anatomy

Е. В. Удут, Federal state budgetary institution “Scientific Research Institute of Pharmacology”, Tomsk, Russian Federation

MD, professor, leading researcher, Laboratory of Pathological Physiology and Experimental Medicine

О. С. Тонких, “International Institute of Biological Systems – Tomsk” Ltd, Tomsk, Russian Federation

PhD, roentgenologist

References

  1. Radzinsky, V.E. Breast cancer and gynecological diseases. Moscow (2010): 302 p.
  2. Filippov, O.S. Benign breast diseases: diagnosis and treatment guidelines. Moscow. MEDpress-Inform (2007): 54 p.
  3. Olawaiye, A., Withhiam-Leitch, M., Danakas, G., et al. “Mastalgia: a review of management.” Gynecol Endocrinol 12.6 (2001): 37–43.
  4. Rozhkova, N.I. X-ray diagnostics of breast diseases. Ed. by A.S. Pavlov. Moscow. Medicine (1993): 227 p.
  5. Guidelines for radiation diagnostics of breast diseases. Ed. 2nd, ext. and rev. Ed. by G.E. Trufanov. Sankt-Petersburg. ELBI-SPb (2009): 351 p.
  6. Vlasov, V.V. Introduction in evidence-based medicine. Moscow. Media Sphere (2001): 392 p.
  7. Gubler, E.V. Informatics in pathology, clinical medicine and pediatrics. Sankt-Petersburg. Medicine (2002): 176 p.
  8. Tsoi, L.K. “Medication therapy of diffuse mastopathy and premenstrual syndrome.” Effective pharmacotherapy. Oncology, Hematology and Radiology 3 (2010): 2–7.
  9. Olawaiye, A., Withiam-Leitch, M., Danakas, G., et al. “Mastalgia: a review of management.” J Reprod Med 12.50 (2005): 933–9.
  10. Tonkikh, O.S., Sotnikova, L.S., Gerget, О.M., et al. The implementation of guidelines for evidence diagnosis of benign mammary dysplasia. Sciense and Education: materials of the II International research and practice conference. S.l. (2012): 474–80.

Downloads

Published

2016-07-15

How to Cite

Сотникова, Л. С., Сотников, А. А., Удут, Е. В., & Тонких, О. С. (2016). The possibility of using mastodynon after endoprosthetics of mammary glands. REPRODUCTIVE ENDOCRINOLOGY, (29), 94–99. https://doi.org/10.18370/2309-4117.2016.29.94-99

Issue

No. 29 (2016)

Section

Drug therapy

License

Copyright (c) 2016 Л. С. Сотникова, А. А. Сотников, Е. В. Удут, О. С. Тонких

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.